GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

This review investigates the various pharmacologic treatments for overweight and obesity in adults, especially glucagon-like peptide 1 (GLP-1) agonists. In light of the globally expanding obesity pandemic and the limited selection of treatments, physicians must be equipped with knowledge regarding p...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2023-03, Vol.40 (3), p.723-742
Main Authors: Moore, Peyton W., Malone, Kevin, VanValkenburg, Delena, Rando, Lauren L., Williams, Brooke C., Matejowsky, Hannah G., Ahmadzadeh, Shahab, Shekoohi, Sahar, Cornett, Elyse M., Kaye, Alan D.
Format: Article
Language:English
Subjects:
Adult
Cardiology
Diabetes Mellitus, Type 2 - drug therapy
Endocrinology
Glucagon-Like Peptide 1 - therapeutic use
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents - adverse effects
Internal Medicine
Medicine
Medicine & Public Health
Obesity - drug therapy
Oncology
Overweight - drug therapy
Pharmacology/Toxicology
Review
Rheumatology
Weight Loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review investigates the various pharmacologic treatments for overweight and obesity in adults, especially glucagon-like peptide 1 (GLP-1) agonists. In light of the globally expanding obesity pandemic and the limited selection of treatments, physicians must be equipped with knowledge regarding proven medications and their nuanced differences to best support patients on their path to a healthier lifestyle. In this review, we explore the current medical therapies for obesity, including all major categories, individual mechanisms of action, pharmacokinetics and pharmacodynamics, adverse effects, risks, and absolute contraindications. Additionally, we review the evidence of four recent clinical trials, two systematic reviews, and two meta-analyses describing the efficacy of GLP-1 agonists in decreasing weight, lowering HbA1c, and improving obesity comorbidities. We also discuss total cost and cost-effectiveness compared to other categories, long-term adherence, barriers to use, and reasons for discontinuation of this drug category. Our goal is that this review can serve as a framework to aid providers in building their knowledge and selecting the most advantageous weight loss medication for each patient.
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-022-02394-w